Topic Editors

Chief Executive Officer and Medical Director, The Cyprus Institute of Neurology & Genetics, P.O. Box 23462, Nicosia 1683, Cyprus
Department of Molecular Genetics, The Cyprus Institute of Neurology& Genetics, PO Box 23462, Nicosia 1683, Cyprus
Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 4980131 Naples, Italy

Advances in Gene Therapy of Human Diseases

Abstract submission deadline
30 November 2026
Manuscript submission deadline
28 February 2027
Viewed by
1241

Topic Information

Dear colleagues,

Gene therapy has made remarkable progress in recent years, offering promising treatment options for a wide range of diseases. Innovative therapeutic developments have shown highly encouraging results in treating many conditions, including inherited disorders, neurological diseases, certain types of cancer, cardiovascular diseases, autoimmune disorders, and rare genetic conditions. Novel therapeutic interventions including gene editing, gene addition, and RNA-based therapies have opened up new avenues for more effective, targeted treatments, bringing hope to patients with previously untreatable conditions.

In this Special Issue, we aim to cover the latest advancements in therapeutic strategies for a wide range of human diseases through original research articles and expert reviews. We will highlight approaches involving gene replacement, genome modification, nucleic acid-based therapies such as antisense oligonucleotides and miRNAs, RNA interference, and innovative delivery systems like viral vectors and nanoparticles.

Prof. Dr. Leonidas A. Phylactou
Dr. Andrie Koutsoulidou
Prof. Dr. Nicola Borbone
Dr. Monica Terracciano
Topic Editors

Keywords

  • gene therapy
  • gene editing
  • antisense oligonucleotides
  • RNA-based therapies
  • miRNAs
  • viral vectors
  • nanoparticle delivery systems

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines
3.9 6.8 2013 21 Days CHF 2600 Submit
BioTech
biotech
3.1 4.8 2012 21.6 Days CHF 1800 Submit
Cells
cells
5.2 10.5 2012 15.5 Days CHF 2700 Submit
Current Issues in Molecular Biology
cimb
3.0 3.7 1999 16.3 Days CHF 2200 Submit
Genes
genes
2.8 5.5 2010 14.6 Days CHF 2600 Submit
International Journal of Molecular Sciences
ijms
4.9 9.0 2000 17.8 Days CHF 2900 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
21 pages, 1368 KB  
Review
Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions
by Edyta Trepkowska-Mejer
Int. J. Mol. Sci. 2026, 27(11), 4663; https://doi.org/10.3390/ijms27114663 - 22 May 2026
Viewed by 85
Abstract
This review summarizes mechanisms regulating mRNA translation under cellular stress and highlights design strategies to improve translation efficiency and stability in the gene therapy of human diseases. mRNA-based therapeutics are emerging as a versatile gene therapy platform enabling transient and controllable expression of [...] Read more.
This review summarizes mechanisms regulating mRNA translation under cellular stress and highlights design strategies to improve translation efficiency and stability in the gene therapy of human diseases. mRNA-based therapeutics are emerging as a versatile gene therapy platform enabling transient and controllable expression of therapeutic proteins for the treatment of cancer, genetic disorders, and inflammatory diseases. The efficacy of mRNA-based gene therapy is strongly influenced by sequence design, chemical modifications, and structural features. Evidence shows that rational mRNA engineering can significantly enhance translation efficiency even under stress conditions that impair canonical protein synthesis, as observed in many pathological states. Cellular stress activates regulatory pathways that suppress global translation; however, optimized mRNA constructs can partially bypass these inhibitory mechanisms, enabling sustained protein expression. By improving mRNA stability and resistance to stress-responsive translational control, robust therapeutic protein production can be achieved even in challenging cellular environments. This article was prepared as a narrative review focused on translational regulation mechanisms relevant to therapeutic mRNA design under cellular stress conditions. Literature was collected from PubMed, Google Scholar, and Web of Science using keywords including “mRNA therapeutics,” “cellular stress,” “translation regulation,” “UTR engineering,” and “cap-independent translation.” Studies published mainly between 2010 and 2025 were considered. Original articles and reviews related to stress-responsive translation and therapeutic mRNA optimization were included, while studies outside the scope of translational control and mRNA engineering were excluded. Priority was given to recent and mechanistically relevant publications. Full article
(This article belongs to the Topic Advances in Gene Therapy of Human Diseases)
Show Figures

Figure 1

16 pages, 3084 KB  
Article
Precise CRISPR-Mediated Editing of the TGFBI R555W Mutation in Patient-Derived Peripheral Blood Mononuclear Cells
by Burak Dagdelen, Hilal Arikoglu, Dudu Erkoc-Kaya and Banu Bozkurt
Int. J. Mol. Sci. 2026, 27(5), 2418; https://doi.org/10.3390/ijms27052418 - 6 Mar 2026
Viewed by 624
Abstract
Over 70 mutations in the transforming growth factor beta-induced (TGFBI) gene are associated with corneal dystrophies that impair vision. The R555W hotspot mutation is a major cause of granular corneal dystrophy type 1 (GCD1). Here, we evaluated the technical feasibility of [...] Read more.
Over 70 mutations in the transforming growth factor beta-induced (TGFBI) gene are associated with corneal dystrophies that impair vision. The R555W hotspot mutation is a major cause of granular corneal dystrophy type 1 (GCD1). Here, we evaluated the technical feasibility of CRISPR/Cas9-mediated editing of the R555W mutation in peripheral blood mononuclear cells (PBMCs) obtained from a patient with GCD1. Three single guide RNAs (sgRNA1–3) and matched single-stranded oligodeoxynucleotide donors (ssODN1–3) were designed and co-transfected into PBMCs. Transfected cells were enriched by flow cytometric sorting, with GFP-positive cells representing approximately 2–4% of the total electroporated population. Editing outcomes were initially screened using high-resolution melting (HRM) analysis, and the sgRNA3–ssODN3 combination identified as the most promising candidate was subsequently validated by next-generation sequencing (NGS). Sequencing revealed a homology-directed repair efficiency of 98.2% among GFP-positive sorted cells, demonstrating efficient and precise genome editing within the enriched population. Because PBMCs are not disease-relevant corneal epithelial cells and only genomic endpoints were assessed, the clinical applicability of this study is limited and the work should be considered a technical proof-of-concept. This framework supports optimization of CRISPR-based strategies prior to studies in biologically relevant corneal models. Full article
(This article belongs to the Topic Advances in Gene Therapy of Human Diseases)
Show Figures

Graphical abstract

Back to TopTop